Assessing renal structural alterations and outcomes

Patent metadata

Field	Value
Publication number	US-2016252528-A1
Application number	US-201615078835-A
Country	US
Kind code	A1
Filing date	Mar 23, 2016
Priority date	Dec 23, 2011
Publication date	Sep 1, 2016
Grant date	—

Abstract

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

First claim

1 . (canceled)

2 . A method for treating a mammal having an increased risk of a poor outcome, wherein said method comprises:
(a) determining that said mammal has an elevated level of urinary NT-CNP-53, (b) monitoring said mammal for the presence of a risk factor for a poor outcome, and (c) instructing said mammal to administer a therapeutic agent to reduce the likelihood of said poor outcome.

3 . The method of claim 2 , wherein said mammal is a human.

4 . The method of claim 2 , wherein said elevated level is greater than 36,000 pg of NT-CNP-53/day.

5 . The method of claim 2 , wherein said elevated level is greater than 42,000 pg of NT-CNP-53/day.

6 . The method of claim 2 , wherein said risk factor is selected from the group consisting of an age factor, hypertension, an elevated serum creatinine level, proteinuria, an elevated body mass index, an elevated cholesterol level, a smoking habit, and diabetes.

7 . The method of claim 2 , wherein said therapeutic agent is an ACE inhibitor, an angiotensin receptor blocker, an aldosterone antagonist, a statin, a native natriuretic peptide, or a designer natriuretic peptide.

Assignees

• Mayo Foundation

Inventors

• Sangaralingham Sasantha J
• Burnett Jr John C
• Cataliotti Alessandro
• Heublein Denise M

Classifications

• A61K38/2242

  Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin · CPC title

• G01N2800/56

  Staging of a disease; Further complications associated with the disease · CPC title

• C07K14/58

  Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin · CPC title

• G01N2800/042

  Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism · CPC title

• G01N2333/58

  Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin · CPC title